News

The company has incurred an operating loss of $15.1m for the three months ended December 31, 2009 as compared to $17.1m for the same period in 2008. The

The acquisition provides AB Sciex with an entry into the liquid chromatography market through the ability to provide instrumentation and consumables used to separate, identify and quantify small

Fostamatinib disodium, which has completed Phase II programme, is the furthest developed oral Spleen Tyrosine Kinase (Syk) inhibitor being evaluated for RA. Under the agreement, AstraZeneca will make

Excluding one-time items, adjusted earnings were 79 cents per share. Revenue totaled $10.09bn in the quarter, an increase of 67%, compared to $6.03bn during the same period last

Linguamatics witnessed corporate growth in 2009, with the addition of new pharmaceutical customers combined with expansion in deployment of the I2E semantic knowledge-discovery platform within existing customers. Linguamatics

Jiangxi Leading Group Office issued an ordinance to add Jiangxi RongYu product, the Tongmai lipid-lowering chew film, to the National Essential Drug List. By the decree of the

Kim Bjornstrup, deputy chairman of Octapharma Group, said: “The development of our novel 10% IVIG is part of our ongoing commitment to invest in the development of protein

The growth is primarily driven by exploration of factors influencing cellular malfunction and disease development. Additionally, innovations in epigenetic studies such as biomarker discovery and scientifically useful biomarker

The company said that Indomethacin for injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750g when after 48